Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics) was established in 2019. It is a biotechnology company dedicated to the innovation and development of novel cell therapies and drugs for the treatment of solid tumors. We focus on developing safer, more effective, more accessible, and more affordable immune cell therapies that are not constrained by any fixed molecular targets and are designed to address both the most prevalent and the most refractory solid tumors. Our core product is the world's first tumor-infiltrating lymphocyte (TIL) therapy that does not require high-intensity lymphodepletion chemotherapy or the use of IL-2 administration. It is positioned to potentially become the first approved TIL therapy in China.

Leveraging our proprietary DeepTIL™ cell enrichment expansion platform，NovaGMP™ non-viral gene-modification platform and RiverTIL™ in vivo TIL platform, we have established a strong technological foundation for continuously developing a pipeline of first-in-class and best-in-class natural and gene-modified TIL therapies. GC101 is the world's first TIL therapy that does not require high-intensity lymphodepletion chemotherapy or the use of IL-2 administration, has brought long-term benefits to patients with advanced metastatic solid tumors who failed multiple lines of treatment, including melanoma, non-small cell lung cancer, cervical cancer, endometrial cancer, pancreatic cancer and glioma. Multiple patients have achieved complete tumor clearance, with the longest tumor-free survival exceeding four years.

GC203 is the world's first non-viral gene-modified TIL therapy. It has obtained NMPA IND approvals for refractory solid tumors such as ovarian cancer and pancreatic cancer. It has already demonstrated favorable efficacy and safety in advanced ovarian cancer patients who have failed multiple lines of treatment.

We are launching the world's first in vivo TIL therapy based on the RiverTIL™ platform. Designed to enable direct in vivo expansion, this therapy has demonstrated great potential to significantly enhance the accessibility of TIL therapy and help transform a personalized treatment into a nearly off-the-shelf cell therapy capable of engaging patients much earlier in their treatment process. 

In terms of financing, we have completed multiple rounds of financing totaling nearly RMB800 million, with continuous support from well-known domestic biopharmaceutical funds such as Kaitai Capital, Oriza Seed, Furong Capital, YuanBio Venture Capital and GZHP Biomedical Industry Investment Fund Management. As the clinical advancement of its core pipeline progresses, Juncell Therapeutics will play an important role in the global cancer treatment field, developing curative and affordable cell therapies to benefit a wide population of patients with solid tumors.